Ninerafaxstat
From Wikipedia, the free encyclopedia
Chemical compound
This article is an orphan, as no other articles link to it . Please introduce links to this page from related articles . (December 2023)
Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | IMB-1018972; IMB-101 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H29N3O5 |
| Molar mass | 415.490g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ninerafaxstat[1] (IMB-1018972 or IMB-101) is a cardiac mitotrope agent investigated by Imbria for diabetic cardiomyopathy,[2] myocardial ischemia, and hypertrophic cardiomyopathy.[3]
References
[edit ]- ↑ "Ninerafaxstat". pubchem.ncbi.nlm.nih.gov. Retrieved 4 December 2023.
- ↑ Hundertmark, M; Siu, A G; Matthews, V; Lewis, A J; Grist, J T; Patel, J; Chamberlin, P; Sarwar, R; Yavari, A; Frenneaux, M P; Valkovic, L; Miller, J J J J; Neubauer, S; Tyler, D J; Rider, O J (3 October 2022). "A phase 2a trial investigating ninerafaxstat – a novel cardiac mitotrope for the treatment of diabetic cardiomyopathy (IMPROVE-DiCE)". European Heart Journal. 43 (Supplement_2). doi:10.1093/eurheartj/ehac544.246 .
- ↑ Chamberlin, Paul; Barrett, Lisa; Buckley, Neil; Mooney, George; Tremaine, Larry; van de Wetering, Jeroen; van Iersel, Thijs; Patel, Jai (May 2021). "Phase 1 Safety and Tolerability Study of Imb-1018972, A Novel Oral Modulator of Myocardial Substrate Utilization Designed to Improve Cardiac Metabolic Efficiency and Bioenergetics". Journal of the American College of Cardiology. 77 (18): 180. doi:10.1016/S0735-1097(21)01539-4 . S2CID 235584926.